In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on OptimizeRx Corporation (Other OTC: OPRX), with a price target of $15. The company’s shares opened today at $10.26, close to its 52-week high of $11.24.
D’silva noted:
“Buy-rated OptimizeRx Corporation (OPRX) reports 2Q18 results AMC on Tuesday, 8/7, and will hold a conference call at 4:30pm ET the same day. The dial-in and conference ID numbers are and 9709267, respectively. We are comfortable with our estimates at this time, as we are modeling sales to be largely flat sequentially, despite the company indicating Q/Q revenue growth throughout 2018. We believe consensus top-line estimates, which are slightly above but still approximate our estimates, are reasonable as well.”
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 26.9% and a 52.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Oramed Pharmaceuticals, and Sorrento Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OptimizeRx Corporation with a $16.50 average price target.
See today’s analyst top recommended stocks >>
Based on OptimizeRx Corporation’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $189.2K. In comparison, last year the company had a GAAP net loss of $361.5K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records (EHR), which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. Its services include EHR workflow solutions such as financial messaging, patient education, and brand messaging; and brand support.
